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enrollment into concurrent clinical trials
Paul S Myles1,2,3*, Elizabeth Williamson4,5, Justin Oakley6 and Andrew Forbes5
Abstract
Researchers and institutional review boards often consider it inappropriate for patients to be asked to consent to
more than one study despite there being no regulatory prohibition on co-enrollment in most countries. There are
however ethical, safety, statistical, and practical considerations relevant to co-enrollment, particularly in surgery and
perioperative medicine, but co-enrollment can be done if such concerns can be resolved. Preventing eligible patients
from co-enrolling in studies which they would authentically value participating in, and whose material risks and benefits
they understand, violates their autonomy - and thus contravenes a fundamental principle of research ethics. Statistical
issues must be considered but can be addressed. In most cases each trial can be analyzed separately and validly using
standard intention to treat principles; selection and other biases can be avoided if enrollment into the second trial is
not dependent upon randomized treatment in the first trial; and valid interaction analyses can be performed for each
trial by considering the patient’s status in the other trial at the time of randomization in the index trial. Clinical research
with a potential to inform and improve clinical practice is valuable and should be supported. The ethical, safety,
statistical, and practical aspects of co-enrollment can be managed, providing greater opportunity for research-led
improvements in clinical practice.
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Introduction
Large, investigator-initiated randomized clinical trials
are able to more fully evaluate the overall effectiveness
of new drugs and other treatments in routine practice
[1-4]. They are often referred to as ‘practical’ or ‘prag-
matic’ trials [2,3], and are usually publicly funded by
national research agencies because they are viewed as
‘public-good’ research [3-5]. There has been a recent
upsurge in interest of methods to avoid waste and ineffi-
ciency in biomedical research [6]. Obtaining adequate
funding for large clinical trials is, however, difficult [7]
and they often compete for researcher interest and pa-
tient recruitment with local research projects and/or
pharmaceutical industry-sponsored trials.
Any patient admitted to hospital for surgery might be
eligible for more than one trial, but there is reluctance
from many clinicians to co-enroll patients because of
ethical, scientific and/or safety concerns. Certainly industry-
sponsored trials typically prohibit co-enrollment, and this,
therefore, reduces opportunity for investigator-initiated
trials. Of greater importance however, is that both re-
searchers and institutional review boards (IRBs) often con-
sider it inappropriate for patients to be asked to consent
to more than one study despite there being no regulatory
prohibition on co-enrollment in most countries [8,9].
Review
Support for co-enrollment in trials has been enunciated
in various fields including critical care [8], emergency
[9], stroke [10], obstetric [11] and neonatal [11-14] medi-
cine trials. There is also ongoing research concerning co-
enrollment in the field of human immunodeficiency virus
clinical trials [15]. The Terry Beirn Community Programs
for Clinical Research on Acquired Immunodeficiency
Syndrome is a clinical trials network funded by the
National Institute of Health. This group encourages co-
enrollment, and has established procedures to optimize
this, including promoting the harmonization of data
collection forms across studies and obtaining patients’
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consent for multiple clinical trials [16]. Given the complex-
ity of surgical patient comorbidity, potential for drug inter-
actions, and possible overlap of clinical studies done by
other disciplines in the perioperative period, co-enrollment
into anesthesia, surgery and other perioperative medicine
trials need specific consideration.
In this article we consider the ethical, practical, financial
and scientific considerations relevant to co-enrollment in
our settings and draw conclusions about when and how
co-enrollment can be implemented.
Ethical considerations
National research and drug administration agencies, as
well as the World Medical Association Declaration of
Helsinki [17], provide ethical guidance to clinical re-
searchers. There are three basic principles that are par-
ticularly relevant to the ethics of research involving
human subjects: respect for persons, beneficence, and
justice [18]. Respect includes acknowledging the rights
of an individual to decide whether or not to join a re-
search study they are offered an opportunity to participate
in (that is autonomy); beneficence includes both ‘patient-
good’ and ‘public-good’ aims of the research; justice refers
to fairness and equity of access to healthcare.
Is preventing patients from co-enrolling in two or
more clinical trials at the same time ethically justifiable?
The autonomy principle underpins the ethical demand
to obtain a person’s properly informed consent to par-
ticipate in a particular study, and to allow them to with-
draw from studies at any time [19]. Preventing patients
from co-enrolling in studies that they would authentic-
ally value participating in, and whose material risks and
benefits they understand, would seem to constitute a re-
striction of their autonomy, but such a restriction would
only count as violating their autonomy when the restric-
tion itself is ethically unjustifiable. Hence, if their partici-
pation would compromise the scientific merit or integrity
of the study, then excluding them from the study does not
violate their autonomy. The ethical demand upon investi-
gators to serve the proper goals of research is subject to
their also meeting certain crucial side-constraints, such as
respecting participant autonomy, and treating participants
and others justly. However, where a patient’s autonomous
co-enrollment in two or more studies would not com-
promise the scientific merit or integrity of those studies,
and would not involve any injustice to other potential
participants (through, for example, causing other relevant
patient groups to be under-represented in these studies),
then denying them the opportunity to participate in these
trials does seem to violate their autonomy.
IRBs often restrict or prevent co-enrollment because
of concerns about the burdens for patients in participating.
To our knowledge, there does not seem to be any empir-
ical research substantiating such an approach. Generally
speaking, intervening in the decisions of a competent or
decisionally-capable person for their own sake constitutes
an exercise of strong paternalism, and is regarded by many
philosophers as ethically unjustifiable [20]. These actions
are distinguished from weak paternalistic interventions,
aimed at protecting or benefiting people who lack deci-
sional capacity, which are usually seen as ethically justifi-
able in certain circumstances [21]. Thus, seeking to protect
decisionally-capable patients by preventing them from
autonomously co-enrolling in two or more studies counts
as an exercise of strong paternalism, which is difficult to
justify ethically. Some philosophers have argued that strong
paternalistic interventions can be ethically justifiable in ex-
ceptional cases, where; for example, a person’s autonomous
decision at a given time removes their capacity and ability
to act autonomously in the future - even John Stuart Mill,
the champion of individual liberty, held that it is ethically
justifiable to prevent a person from voluntarily selling
themselves into slavery [22]. However, there is a heavy bur-
den of proof upon such arguments to demonstrate that
such strong paternalistic interventions are necessary in the
circumstances to prevent the person altogether relinquish-
ing their future capacity for autonomy. And it is far from
clear that co-enrollment in two or more clinical trials, gen-
erally speaking, threatens to remove patients’ capacities to
act autonomously in the future.
Rejecting general prohibitions on co-enrollment is also
consistent with key national guidelines and principles of
research ethics, which take beneficence, respect for per-
sons, and justice as central values governing the ethical
conduct of research. Such prohibitions are not usually
based on concerns about justice to participants, and pa-
tients need to have an opportunity to make their own
autonomous decisions about whether or not to co-enroll
in two more studies which meet the criteria for scientific
merit and integrity. Indeed, allowing co-enrollment can
enable research to be done more efficiently, which itself
can be an important factor in the just allocation of the
financial and other resources which are available to in-
vestigators to conduct research.
Respect for personal autonomy - the capacity to make
one’s own decisions in life according to one’s own values
and interests as to what constitutes a meaningful life
[19] - is a key ethical requirement. As stated in the
Belmont Report in 1979 [18], to the degree that research
subjects are capable, they should be given the opportun-
ity to choose what shall or shall not happen to them.
Investigators cannot be required to withhold information
about potential studies from a prospective participant
merely because they would entail co-enrollment. It is
only after the likely personal and societal benefits, and
possible costs and harms, of participating in one or more
studies have been clearly communicated to the person
that they can make an informed decision about whether
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to participate in those studies. But it is not only the
details of a particular study that need explanation, it is
also the existence of such a study - for denial of the
opportunity to participate in a study that they wish to
participate in and for which they meet the inclusion cri-
teria denies the potential participant autonomy. Potential
study participants should be offered the opportunity to
decide whether or not a particular research project is
too burdensome. Anything less would seem in itself,
unethical.
IRB members have a responsibility to protect the inter-
ests of study participants, but this does not mean they
should decide what is best for participants. A person’s
values and motivations deserve consideration and these
remain unknown until the person is approached. An
additional consideration would be to ask potential study
participants to choose their preferred one or more of
several current trials [23].
Perspectives of patients and researchers
Previous studies have demonstrated that potential partic-
ipants in clinical trials, including parents of children and
next-of-kin of critically ill patients, strongly support par-
ticipation in research [12-14]. Numerous surveys have
noted that altruism [12,24,25], and perhaps the possibil-
ity of receiving a new and potentially superior treatment,
are key motivations for participants to enroll in clinical
research projects.
Parents of infants receiving intensive care who had
either agreed or declined consent to their child’s partici-
pation in research were asked about which factors influ-
enced their decision [13]. The most important aspects
were the parents’ risk-benefit assessment, their attitude
towards research, and the integrity of the consent process.
Around one third of the parents preferred the doctors to
advise them rather than make an independent decision. In
another study, parents of premature infants reported they
were mostly comfortable with their child being enrolled in
more than one study at any one time [12]. A clear majority
(71%) of the parents thought it was very good for their
baby to be in a hospital that was carrying out a lot of
research. Most (93%) thought that their baby would get
the same or better care. Only 22% were worried about the
number of studies; and 74% were willing for their baby to
participate in 2 or more studies, and 10% would enroll
in all 7 proposed studies. Importantly, there was direct
support for the public good stance outlined above, in that
most parents (94%) believed that their baby’s participation
would improve care of future babies.
Cook et al. [8] conducted a survey of critical care re-
searchers from the Canadian Critical Care Trials Group
and the Australian and New Zealand Intensive Care
Society Clinical Trials Group regarding enrollment of
critically ill children and adults into one or more studies.
They found that only 11% of their respective IRBs had a
formal co-enrollment policy and even then, these pol-
icies were highly variable.
Interestingly, the lay public seems to be less supportive
of enrollment into a randomized trial when compared
with actual patients who have a medical condition [26],
suggesting that values and preferences of members of an
IRB and actual patients may not align. That is, IRB mem-
bers may be too conservative and thus fail to represent
the interests of the potential participants of clinical re-
search. Burden should be primarily determined by the
study participant, and this cannot be resolved unless the
potential participant is informed of the proposed research.
Safety considerations
Many investigators believe that if patients are enrolled in
two or more clinical studies the effects of each intervention
may interfere with one another. Unexpected drug-drug in-
teractions could be potentially unsafe for the co-enrolled
study participants. This possibility should always be care-
fully considered before co-enrollment is undertaken. It will
be a concern particularly when two studies are testing
drugs that can directly interact with each other (for
example, two anticoagulants), and most early-phase
drug development studies where the effects and side
effects of the investigational drug remain unclear. Of
course, such interactions can occur outside the auspices
of a randomized trial. Most perioperative and critical care
studies enroll patients with several comorbidities treated
with a range of co-administered medications. A cursory
look at the tabulated baseline characteristics in most
perioperative phase III/IV drug trials shows that the
many types of medication that participants are taking in
addition to the trial drug attests to the potential for
interactions. In other words, co-enrollment into several
drug trials is little different from what occurs in
single-enrollment studies. Adverse drug interactions
may occur in any case. There should be clear guide-
lines for the detection and reporting of adverse events
in all drug trials [27].
Scientific and statistical considerations
The key scientific concern surrounding co-enrollment is
that by enrolling patients into two or more trials the sci-
entific validity of the individual trials may be threatened.
In particular, it is possible that the effects of the individ-
ual interventions could interfere with each other. Such
drug-drug interactions could potentially change the ef-
fects of each individual intervention, thereby leading to
different conclusions from those that would have been
drawn if the two trials had been conducted on separate
patient populations. A second concern is the potential
effect of co-enrollment on the statistical power of the in-
dividual trials.
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Effect of co-enrollment on ability to assess drug-drug
interactions
The relevance of the first statistical concern, that of
drug-drug interaction, is very dependent on the specific
scenario under consideration. Here we are considering
the context of phase III/IV pragmatic trials in the field
of anesthesia, which are conducted with a heterogeneous
population receiving other drug treatments for their
underlying condition(s). Clinical trials that allow a broad
range of study participants and options for drug treat-
ment(s) and other therapies are highly valued because
they provide greater external validity, or generalizability,
of the trial results [1,2,4]. Phase III/IV trials typically in-
clude patients with comorbidities for which drug-disease
interactions may occur, as well as a variety of non-drug
treatments affecting outcome. The interventions being
evaluated tend to be commonly used in practice albeit in
a non-randomized fashion, being at the discretion of the
anesthesiologist and other treating physicians. These clin-
ical trial participants are therefore exposed to drug and
other treatment interactions in a largely uncontrolled and
poorly evaluated fashion. In these circumstances, rather
than introducing previously absent drug-drug interactions,
co-enrollment facilitates evaluation of such interactions,
at least to some degree.
A more deliberate approach to the simultaneous evalu-
ation of two or more interventions would be to adopt a
factorial design [28]. This is a robust and efficient ap-
proach, particularly if there is a low likelihood of inter-
action between the interventions. Factorial designs are
cost-efficient, testing two or more treatments for the
price of one [5,28]. Larntz et al. [16] point out that sub-
groups defined by randomized treatment assignment
protect against imbalance or confounding; thus, a factorial
design allows unbiased assessment of interaction between
the interventions. As with many interaction analyses,
these assessments can have low statistical power. How-
ever, Lilford et al. [5] note that the argument that fac-
torial trials may miss interactions between interventions
is specious because the alternative is that separate trials
will miss any such interactions.
A good example of a factorial design in anesthesia is
the IMPACT trial testing six anti-emetic interventions
[29]. The study was primarily designed to determine the
relative benefit of several antiemetic interventions. The
6-way factorial design meant that 8 antiemetic combina-
tions could be evaluated, with 64 (2 × 2 × 2 × 2 × 2 × 2)
possible drug-drug combinations. The investigators found
that ondansetron, dexamethasone, and droperidol each re-
duced the risk of postoperative nausea and vomiting by
about 25%; propofol reduced the risk by 19% and avoid-
ance of nitrous oxide (replaced with air) 12%. This design
allowed the researchers to determine that all the interven-
tions acted independently of one another.
A key question is whether co-enrolled trials can pro-
vide some of the same advantages as factorial trials when
the enrollment and randomization is not concurrent.
Clearly, co-enrollment shares the advantage of requiring
fewer participants in total. As we will demonstrate, co-
enrolled trials also allow the unbiased assessment of
interaction between interventions provided that suffi-
cient numbers of participants are co-enrolled. However,
extra care is needed in the construction of appropriate
interaction analyses compared with a factorial trial.
The reason why evaluating drug-drug interactions is
not straightforward in co-enrolled trials is that conven-
tional interaction analyses are prone to bias when based
on the subset of patients who are enrolled in both trials.
This bias arises when the randomized intervention
allocated in one trial influences enrollment into a sub-
sequent co-enrolled trial, and enrollment in the subse-
quent trial depends on health status (as it almost always
will). To illustrate this point, we consider a simplified ex-
ample of two trials, S and T, with enrollment to S always
occurring before enrollment to T. Schematically, the time
sequence is presented in Figure 1.
Suppose patients in Trial S take a range of concomi-
tant medications, some including a Drug X prescribed to
patients in generally poor health status. Patients are ran-
domly assigned to one of two treatments, S1 and S2.
Due to randomization, the use of Drug X will be bal-
anced between treatment arms S1 and S2. Suppose that
the later Trial T has the following determination for
entry: either a patient has not taken Drug X, or the pa-
tient has received treatment S1 in Trial S. Then, among
patients in Trial S who are also enrolled later in Trial T,
those who are taking Drug X must necessarily have re-
ceived treatment S1. This means that among patients
enrolled in both trials the patients receiving S1 are less
healthy than those receiving S2, thereby ruining the bal-
ance in underlying health status in this subgroup that
randomization had provided among all Trial S patients.
In causal modeling language, this is known as (selection)
‘bias from conditioning on a collider’ [30] and has also
been discussed in the context of adjustment for post-
randomization variables [31]. The consequence of this
selection bias is that we cannot validly compare the
effect of S1 (compared to S2) between patients who re-
ceived the active intervention in Trial T, and similarly
we cannot compare S1 versus S2 among patients receiv-
ing the control intervention in Trial T. We therefore
cannot answer the question of whether the difference in
effects of the treatments S1 and S2 evaluated in Trial S
was modified by the intervention received in Trial T.
However, there is a fundamental asymmetry between
Trials S and T due to their temporal ordering of enroll-
ment: we can assess whether the difference in effects of
the drugs evaluated in Trial T (T1 and T2) was modified
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by the intervention received in Trial S, since treatment
in Trial S is a pre-randomization characteristic at the
time of randomization for Trial T.
In co-enrolled trials where participants can be enrolled
into either of two trials first, this idea can be extended,
showing that the effect-modification of each drug by the
other can be assessed, provided that the enrollment and
randomization status of the other trial at the time of
randomization into the index trial is taken into account.
This is discussed in detail by Larntz et al. [16] in the
context of co-enrolled human immunodeficiency virus
trials. In brief, we compare the effect of the active drug
being evaluated in Trial T between participants who had
been randomized to S1 and S2 at the time of their enroll-
ment to Trial T (so participants who were not enrolled into
Trial S at the time of enrollment into Trial T are not in-
cluded in this analysis, irrespective of later enrollment into
Trial S), and vice versa. Therefore, when considering inter-
actions, we need to emphasize the fundamental importance
of the status of each patient at the time of randomization
in each trial. Patients enrolled and randomized to treat-
ments T1 and T2 in Trial T after randomization to Trial S
are regarded as not enrolled in T when interactions be-
tween treatments in Trials S and T are being considered.
Thus, naïve attempts to examine interactions based on
a posteriori allocated treatments without regard to their
timing are prone to selection bias and would need to be
justified on substantive grounds why such bias is not
plausible. An example where this may be justified is with
double-blind trials where there may be little opportunity
for allocated treatment in the first trial to influence en-
rollment into the second trial. However, even in this case
side effects from one of the blinded treatments may
make participation in the second trial less likely, leading
again to selection bias. Furthermore, it may be tempting
to also consider trials with apparently simultaneous en-
rollment of patients as being justified. However, even in
such situations a patient must enroll in the trials sequen-
tially, no matter how small the time interval between
enrollments. If randomized allocation to the first trial
occurs immediately after enrollment and prior to enroll-
ment in the second trial then bias may occur if there is
opportunity for that allocation to influence enrollment.
The only occasion where there is truly no bias potential
is with proper factorial designs, with effectively two trials
run together with absolutely concurrent enrollment and
randomization.
Our discussion thus far has concerned concepts of
interaction and its effects. Also of importance are standards
for conducting and reporting analyses where interactions
are present, and guidelines for these are available [32,33].
Note on interpretation of results of individual trial analyses
in the presence of an interaction
Co-enrollment into two or more trials does not invali-
date the original randomization of the individual trials.
Separate analysis of each individual trial, ignoring the
issue of co-enrollment into the other trial, will retain the
balance of patient characteristics expected by standard
random assignment within each trial. However, although
analysis of an individual Trial S can proceed ignoring
the presence of interventions in Trial T, if there are in-
teractions between the interventions of the two trials
then the estimated treatment effects in Trial S is a
weighted average of the effects at each level of the treat-
ments of Trial T. It therefore estimates the treatment
effect in a hypothetical population where patients receive
both treatments in the same proportions as in Trial S.
This may or may not correspond to any actual patient
population of interest depending on how realistic the
concurrent treatment usage patterns are in actual prac-
tice. As a result the generalizability of the results of the
individual trials may potentially be compromised.
Effect of co-enrollment on statistical power
We now turn to the second scientific and statistical
concern with co-enrollment; the potential effect of co-
enrollment on the statistical power of the individual
trials. Co-enrollment can change the outcomes from that
of the natural course of treatment for patients enrolled
in an initial trial. For example, for patients enrolled in
Trial S initially, the natural course may be that patients
receive later, in non-randomized manner, treatment T1
with probability 20% and treatment T2 with probability
80%. (In practice, these probabilities would depend on
patient clinical characteristics). However, if co-enrolled
later in Trial T these probabilities shift to 50% due to
1:1 randomization, and therefore if there is differing effi-
cacy of T1 and T2, the outcomes of patients in Trial S
in the absence of Trial T will differ to the outcomes in
the presence of Trial T. Although intention to treat ana-
lysis of Trial S ignoring Trial T status will not be biased
for estimating the effect of randomization to treatments
S1 versus S2, the power of Trial S will be altered to
Figure 1 A schematic representation of the time sequence of enrollment and randomization in the two trials.
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some degree by the altered prognosis of patients later
randomized in Trial T. Note that this altered prognosis
of patients would occur even if Trials S and T were run
concurrently as in a factorial trial, so this power issue is
not at all unique to sequentially co-enrolled trials.
We have examined numerically a number of scenarios
of enrollment into an initial Trial S then possible co-
enrollment into a second Trial T. The statistical power
for treatment comparisons in the initial Trial S depends
on a range of factors, including the amount of co-
enrollment, the altered prognosis of patients due to the
existence of a true effect of either or both treatments T1
and T2, the existence of an interaction between the
treatments in Trials S and T1 and T2, the severity of
condition of the patient population, the eligibility criteria
for Trial T, and the use of treatments T1 and T2 in pa-
tients enrolled in S but not enrolled in the second Trial
T. General conclusions are not easily summarized due to
the wide variety of input parameters. However, for any
proposed co-enrollment situation, although investigators
cannot change the effects of the two interventions or
their interaction, they can potentially control the co-
enrollment fraction. Therefore, we investigate the impact
of the co-enrollment decision in situations where all
design characteristics and effects of treatments in Trial
S and T are held fixed. We provide some numerical
results here for the following situations which we con-
sider fairly representative of large scale investigator-
initiated trials:
 There is a binary classification of disease severity,
and either 60% or 30% of patients in Trial S are
classified as severely diseased
 The probability of enrollment in Trial T does not
depend on disease severity of the patient
 Patients not enrolled in Trial T may receive
treatments T1 and T2 of Trial T. We consider 3
cases: (i) treatment T1 is universally used;
(ii) treatment T2 is universally used; (iii) patients
received treatment T1 with probability according to
their disease severity: 30% of severely diseased
patients receive treatment T1, 60% of non-severely
diseased patients receive T1
 All patients receive their assigned treatment, with
no crossover or dropout
 The statistical model for event rates is a linear
model with interaction, which can be expressed as
the probability of a poor outcome for non-severely
diseased patients:
7% if receive S2 and T2
5% if receive S1 and T2
6% if receive S2 and T1
Add Q% if receive S1 and T1 (amount Q will be
varied)
And add 3% to each of the above outcome
probabilities if the patient is severely diseased
 We assume the same statistical model for event
rates applies regardless of whether patients are
co-enrolled in Trial T or not. That is, the event rate
depends on which treatment of Trial T is received,
regardless of whether or not it is received in Trial T
or external to it.
In statistical terms we write the model as:
Pr poor outcomeð Þ ¼ 7% − 2% if treated with S1ð Þ
– 1% if treated with T1ð Þ
þ Q% if treated with both S1 and T1ð Þ
þ 3% if severely diseasedð Þ
We consider three values of Q, namely −1%, 0, and +1%,
corresponding to a synergistic interaction between the
treatments in S and T; no interaction; and an antagonistic
interaction, respectively. A synergistic interaction between
treatments S1 and T1 means that their combined effect is
larger than that predicted from their individual effects.
An antagonistic interaction has the combined effect less
than predicted from the individual effects. In the above
model, the synergism and antagonism are the same size
as the effect of treatment T1, and therefore these are
quite large effects.
Figure 2 displays the dependence of the required sam-
ple size on the co-enrollment fraction for each of the
four cases of use of Trial T treatments outside of Trial
T. We can provide a general intuitive explanation for
why co-enrollment might be expected to produce large
or small increases or decreases in required sample size.
The main element concerns the amplification or dimin-
ishment of the effect of the interaction between the
treatments of the two trials according to the frequency
of use of treatment T1 in the non-co-enrolled patients
of Trial S, that is, the frequency of use of treatment T1
outside of Trial T.
First, synergistic interactions tend to increase statis-
tical power (and hence have reduced sample size re-
quirements), whereas antagonistic interactions decrease
power [32]. Therefore, the effects of co-enrollment on
power will depend both on the direction of the inter-
action, and also on whether co-enrollment increases or
decreases the ‘exposure’ of patients in Trial S to the re-
ceipt of treatment T1 of Trial T, and hence to the inter-
action. The greater the proportion of patients in Trial S
exposed to treatment T1, the greater the effects of the
interaction.
This can be summarized succinctly: if co-enrollment
increases the proportion of patients in the first Trial S
receiving treatment T1, then an antagonistic interaction
will increase required sample size for the first trial, but a
synergistic interaction will decrease sample size. Scenario
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(4) of Figure 2 displays this case - with zero co-enrollment
and no exposure to treatment T1 outside of Trial T, then
no patients in Trial S receive treatment T1 and interaction
has a moot null effect. If there is 100% co-enrollment then
all patients in Trial S receive treatment T1 and the inter-
action has maximal effect on Trial S patients in the direc-
tions anticipated by synergism and antagonism.
Analogously, if co-enrollment decreases the propor-
tion of patients in the first Trial S receiving T1 then an
antagonistic interaction decreases the required sample
size and a synergistic interaction increases sample size.
This is displayed in Scenario (1) of Figure 2 where zero
co-enrollment means all patients in Trial S are treatment
with treatment T1 and hence maximal interaction effects
are observed. With 100% co-enrollment, then only 50%
of patients are exposed to T1 (because of randomization
in Trial T) and hence the effect of the interaction is
reduced.
For intermediate scenarios, such as Scenarios (2) and
(3) of Figure 2, the effects of co-enrollment on sample
size depends on the exposure of non-co-enrolled patients
to T1 outside of Trial T relative to that of 50% exposure
for co-enrolled patients (because of randomization in Trial
T). If non-co-enrolled exposure to T1 is greater than 50%
then the greater the co-enrollment the less the overall
exposure of patients of Trial S is to treatment T1 and
hence the less the impact of the interaction. Conversely, if
non-co-enrolled exposure to T1 is less than 50%, then
the greater the co-enrollment the greater the impact of
the interaction.
In the Appendix we show that for Scenario (2) of Figure 2
the non-co-enrolled exposure to T1 is 42%, and hence the
greater the co-enrollment the greater the impact of the
synergistic and antagonistic interactions. However, these
effects are rather mild, with the synergistic interaction
yielding at most a 9% increase in sample size required.
For Scenario (3) of Figure 2, the Appendix shows that
the non-co-enrolled exposure to T1 is 51%, and therefore
non-co-enrolled patients are receiving T1 at the same pro-
portion as co-enrolled patients and co-enrollment has
negligible impact on sample size.
More generally, we have found empirically that for
studies with primary endpoints in the range of 5% to
10% that co-enrollment has a small effect on study
power, mostly resulting in less than a 20% difference
between smallest and largest sample sizes. However, we
caution that this need not always be the case - in the
Appendix we describe situations with rather extreme
antagonistic interactions where co-enrollment may have
a substantial impact on sample size.
Therefore, for the simplified setting considered above
of an initial Trial S followed by potential co-enrollment
in Trial T, for co-enrollment to have a large detrimental
effect on the sample size of the initial Trial (S), there
needs to be a large antagonistic interaction, substantial
co-enrollment, and patients not co-enrolled receive
treatment T1 at a lower frequency than 50%. Whether
this is likely to occur will of course depend on the par-
ticular clinical circumstances of the trials and treatments
under consideration.
We now summarize all the statistical issues discussed
above:
If it is reasonable to assume that:
(i) The randomized treatment in the first trial has not
influenced enrollment into the second trial, and
(ii) That neither treatment influences the natural course
of disease of the other condition being studied, and
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size
per group
Percentage of Trial S patients co-enrolled into Trial T
Use of Trial T intervention T1 in patients not co-enrolled in Trial T
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Interaction between Trial S and Trial T interventions:
Figure 2 Sample size per arm to detect a difference between interventions in Trial S with 90% power for 4 scenarios according to
co-enrolled fraction in later Trial T. Scenario (1) corresponds to treatment T1 of Trial T used for all non-co-enrolled patients. Scenarios (2) and
(3) correspond to preferential use of T1 in non-co-enrolled patients depending on their severity. Scenario (4) corresponds to no use of T1 in
non-co-enrolled patients.
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(iii) That there is unlikely to be a drug-drug interaction,
then the scientific validity of the individual trials should
not be compromised or complicated by co-enrollment.
Violation of any of these conditions means that careful
consideration of the issues explained above is required.
Practical and cost-effectiveness considerations
Clinical research with a potential to inform and improve
clinical practice is valuable and should be supported
[2,3,10,34]. It has often been noted that there is a lost
opportunity in most areas of clinical practice, because a
majority of patients are not participating in clinical
trials.
A select few departments and/or institutions have
established clinical research infrastructure, and often
lead multinational, multicenter trials that provide fund-
ing, typically on a per patient basis, to numerous other
‘secondary’ sites. These secondary sites are dependent on
patient recruitments to fund their local research staff, but
this research income does not necessarily cover costs. Op-
portunities for local sites to co-enroll patients into a num-
ber of projects could generate higher income for them
and so bolster their involvement in research. More studies
can be done in a timely fashion and more information to
guide clinical practice can be generated [3,6,35,36].
Conclusion
Overall, the ethical, scientific and safety aspects of co-
enrollment can generally be managed, providing greater
opportunity for research-led improvements in clinical
practice. Researchers should consider the various re-
search projects for which patients may be eligible. The
main issues to consider are whether study-related proce-
dures might increase study burden on the participants,
the impact that co-enrollment might have on study
power and on the potential for selection bias of inter-
action analyses.
Appendix
Details of the computation of sample size according to
co-enrollment fraction
Let N denote the total number of patients in Trial S. Of
these N patients, a proportion will be co-enrolled in
Trial T, and the remainder will receive one of the treat-
ments of Trial T (without being co-enrolled in Trial T)
with probability according their severity.
Let Pijcs be the outcome probability for a patient who
receives treatment i in Trial S (i = 1 if S1, i = 2 if S2),
treatment j of Trial T (j = 1 if T1, j = 2 if T2), has co-
enrollment status c (c = 1 if co-enrolled in both trials,
c = 2 if enrolled in Trial S only), and is of underlying
severity s (s = 1 for severe, s = 2 for non-severe).
Because the outcome probability only depends only on
treatments S and T received and patient severity, regard-
less of whether the patients are actually co-enrolled in
Trial T or not, Pij1s = Pij2s.
Let nijcs be the number of patients receiving treatment
i in Trial S, treatment j of Trial T, are of co-enrollment
status c, and are of severity s.
Note that due to randomization, co-enrolled patients
are allocated to each combination of treatments S (1,2)
and T (1,2) with probability 1/4. Also note that for pa-
tients not co-enrolled, since the probability of their re-
ceipt of treatments T1 or T2 depends solely on their
severity and not on treatment received in Trial S, 1/2 of
patients receiving treatment T1 will have received treat-
ment S1 and 1/2 will have received S2, and similarly for
patients receiving T2.
Therefore, for co-enrolled patients:
nij1s ¼ N Pr Coenrolledð Þ  Pr Severity ¼ sð Þ  14
And for non-co-enrolled patients:
nij0s ¼ N Pr Not coenrolledð Þ  Pr Severity ¼ sð Þ
 P Receive treatment j of Trial T Severity ¼ sÞ  1
2


Then the marginal event rate for each treatment i of
Trial S is
Pi ¼
X2
j¼1
X2
c¼1
X2
s¼1 nijcsPijcsX2
j¼1
X2
c¼1
X2
s¼1nijcs
Sample size formula
Once marginal event rates P1 and P2 for Trial S have
been determined, the sample size per arm of Trial S is
then [37]:
N ¼
Zα
2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2P 1−Pð Þ
p
þ Zβ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
P1 1−P1ð Þ þ P2 1−P2ð Þ
p 2
P1−P2ð Þ2
where P ¼ P1þP22 ; and Za2 and Zβ are quantiles of the
standard normal distribution for type I error rate α and
power 1 − β.
Calculation of the probability of non-co-enrolled patients
receiving treatment T1 of Trial T
Using the specified probabilities for non-co-enrolled pa-
tients receiving treatment T1 of Trial T in the example
in the main text, where Pr(T1 = 1 | Severe) = 0.30, and
Pr(T1 = 1 | Non-severe) = 0.60, there are two cases:
(i) 60% of patients are severely diseased
(ii)30% of patients are severely diseased
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For these cases:
(i) Pr(Severe) = 0.60:
Pr T1 ¼ 1ð Þ ¼ PrðT1 ¼ 1jSevereÞ  Pr Severeð Þ
þ PrðT1 ¼ 1jNon−severeÞ  Pr Non−severeð Þ
¼ 0:30  0:60 þ 0:60  1−0:60ð Þ ¼ 0:42
(ii)Pr(Severe) = 0.30:
Pr T1 ¼ 1ð Þ ¼ PrðT1 ¼ 1jSevereÞ  Pr Severeð Þ
þ PrðT1 ¼ 1jNon−severeÞ  Pr Non−severeð Þ
¼ 0:30  0:30 þ 0:60  1−0:30ð Þ ¼ 0:51
Numerical examples of effect of co-enrollment
Here we provide additional numerical examples of the
effect of co-enrollment on sample size under varying
conditions of size of antagonistic interaction and propor-
tion of patients who are severely diseased:
(a) Table 1 above reports the results of calculations
with the same model as in the main text but with an
antagonistic interaction of 2%, representing a large quali-
tative interaction where the effect of S1 in the presence
of T1 is 0% (that is neutral), and in the absence of T1
is –2%, that is benefit). We note the sample size differ-
ential between no co-enrollment and full co-enrollment
is approximately 35% (= 15,097/11,219).
(b) Table 2 extends this further to the case where the
antagonistic interaction is +3%: the effect of S1 in the
presence of T1 is +1% (that is harm), and in the absence
of T1 is –2% (benefit). The sample size differential be-
tween no co-enrollment and full co-enrollment is now
120%, owing to convergence of the event rates and full co-
enrollment reducing the difference in event rates by 33%.
(c) Table 3 also considers an antagonistic interaction
of 3% but now considers a population where 30% of pa-
tients are severely diseased. Here we see a different out-
come - there is little change in required sample size as
co-enrollment increases, and in fact there is a reduction
in sample size of 12%. This difference compared to
Table 2 is explained in the main text - it is simply be-
cause the exposure fraction of non-co-enrolled patients
to treatment T1 is approximately 50% in this case, com-
pared to 42% in Table 2.
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Table 2 Co-enrollment fractions and resultant sample size
with 3% antagonistic interaction
Co-enrollment
fraction
Event rate
for arm S1
Event rate
for arm S2
Difference Number of
patients per
arm for
90% power
0% 7.64 8.38 -0.74 28,249
30% 7.69 8.36 -0.67 34,715
50% 7.72 8.34 -0.62 40,335
70% 7.75 8.32 -0.57 47,432
100% 7.80 8.30 -0.50 62,161
Table 3 Co-enrollment fractions and resultant sample size
with 2% antagonistic interaction and an at-risk study
population
Co-enrollment
fraction
Event rate
for arm S1
Event rate
for arm S2
Difference Number of
patients per
arm for
90% power
0% 6.92 7.39 -0.47 63,137
30% 6.91 7.39 -0.48 60,775
50% 6.91 7.40 -0.48 59,272
70% 6.91 7.40 -0.49 57,825
100% 6.90 7.40 -0.50 55,751
Table 1 Co-enrollment fractions and resultant sample size
with 2% antagonistic interaction
Co-enrollment
fraction
Event
rate for
arm S1
Event
rate for
arm S2
Difference Number of
patients per arm
for 90% power
0% 7.22 8.38 -1.16 11,219
30% 7.24 8.36 -1.11 12,209
50% 7.26 8.34 -1.08 12,943
70% 7.28 8.32 -1.05 13,746
100% 7.30 8.30 -1.00 15,097
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